Halozyme Therapeutics Investor Presentation — February 2021

Document content

Fourth Quarter and Full Year 2020 Financial Results Presentation

February 23, 2021Forward -Looking Statements

In addition to historical information, the statements set forth in this presentation include forward -looking statements includin g,

without limitation, statements concerning the Company’s expected future financial performance (including the Company's

financial outlook for 2021) and expectations for profitability, revenue (including expectations for future milestones and roy alty

growth), operating income, expenses and earnings -per-share and the Company’s plans to continue its share repurchase

program and to potentially expand its platform through acquisitions. Forward -looking statements regarding the Company’s

ENHANZE®drug delivery technology may include the possible activity, benefits and attributes of ENHANZE®,the possible method

of action of ENHANZE®,its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and

facilitating more rapid delivery of injectable medications through subcutaneous delivery. Forward -looking statements regarding

the Company's ENHANZE®business may include potential growth driven by our partners' development and commercialization

efforts (including anticipated new clinical trial starts and product launches), projections for future sales revenue of our

collaborators’ products, potential new ENHANZE®collaborations and collaborative targets and regulatory review and potential

approvals of new ENHANZE®products. These forward -looking statements are typically, but not always, identified through use of

the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "p otential,"

"possible," "should," "continue," and other words of similar meaning and involve risk and uncertainties that could cause actu al

results to differ materially from those in the forward -looking statements. Actual results could differ materially from the

expectations contained in these forward -looking statements as a result of several factors, including unexpected levels of

revenues (including royalty and milestone revenue received from our collaboration partners), expenditures and costs, inabilit y to

sustain profitability, unexpected delays in the execution of the Company's share repurchase program or planned platform

expansion, unexpected results or delays in the growth of the Company’s ENHANZE®business, or in the development, regulatory

review or commercialization of ENHANZE®products, including any potential delays caused by the current COVID -19 global